FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Torsten Haferlach

Research Profile

Disorders

Physiology

Mutation

Procedures

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Vera Grossmann; Claudia Haferlach; Torsten Haferlach; Wolfgang Kern; Alexander Kohlmann; Niroshan Nadarajah; Andreas Roller; Christiane Eder; Annette Fasan; Elisa Stopp; Sandra Weissmann; Susanne Schnittger
CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.
Verena Patterer; Susanne Schnittger; Torsten Haferlach; Wolfgang Kern; Claudia Haferlach
Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.
Wolfgang Kern; Susanne Schnittger; Tamara Alpermann; Ulrike Bacher; Claudia Haferlach; Torsten Haferlach
Multiparameter flow cytometry reveals myelodysplasia-related aberrant antigen expression in myelodysplastic/myeloproliferative neoplasms.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Torsten Haferlach (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Vera Grossmann; Claudia Haferlach; Torsten Haferlach; Wolfgang Kern; Alexander Kohlmann; Niroshan Nadarajah; Andreas Roller; Christiane Eder; Annette Fasan; Elisa Stopp; Sandra Weissmann; Susanne Schnittger
CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.
British journal of haematology 2013;161(5):649-58.
2013: Verena Patterer; Susanne Schnittger; Torsten Haferlach; Wolfgang Kern; Claudia Haferlach
Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.
Annals of hematology 2013;92(6):759-69.
2013: Wolfgang Kern; Susanne Schnittger; Tamara Alpermann; Ulrike Bacher; Claudia Haferlach; Torsten Haferlach
Multiparameter flow cytometry reveals myelodysplasia-related aberrant antigen expression in myelodysplastic/myeloproliferative neoplasms.
Cytometry. Part B, Clinical cytometry 2013;84(3):194-7.
2013: Vera Grossmann; Claudia Haferlach; Torsten Haferlach; Wolfgang Kern; Franziska Poetzinger; Andreas Roller; Sonja Schindela; Susanne Schnittger; Kathrin Stadler; Sandra Weissmann; Frauke Bellos; Alexander Kohlmann
The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL.
Genes, chromosomes & cancer 2013;52(4):410-22.
2013: Tamara Alpermann; Claudia Haferlach; Wolfgang Kern; Karl-Anton Kreuzer; Hermann Josef Pielken; Christoph Schmid; Norbert Schmitz; Susanne Schnittger; Hubert Serve; Clemens-Martin Wendtner; Torsten Haferlach
Evaluation of the proposed reporting system of the European LeukemiaNet and recommendations for prognosis of acute myeloid leukemia.
Leukemia research 2013;37(2):197-200.
2013: Ulrike Bacher; Torsten Haferlach; Wolfgang Kern; Susanne Schnittger; T Alpermann; Claudia Haferlach
Molecular mutations are prognostically relevant in AML with intermediate risk cytogenetics and aberrant karyotype.
Leukemia 2013;27(2):496-500.
2013: A Fasan; V Grossmann; Claudia Haferlach; Torsten Haferlach; Wolfgang Kern; Alexander Kohlmann; Frank Dicker; C Eder; Susanne Schnittger
GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis.
Leukemia 2013;27(2):482-5.
2013: Annette Fasan; Vera Grossmann; Claudia Haferlach; Torsten Haferlach; Wolfgang Kern; Alexander Kohlmann; Andreas Roller; Tamara Alpermann; Christiane Eder; Susanne Schnittger
Frequency and prognostic impact of CEBPA proximal, distal and core promoter methylation in normal karyotype AML: a study on 623 cases.
PloS one 2013;8(2):e54365.
2013: Eva Lengfelder; Carsten Müller-Tidow; Cristina Sauerland; Stephanie Schneider; Susanne Schnittger; Beate Schultheis; Hubert Serve; Karsten Spiekermann; Bernhard Wörmann; Carlo Aul; Wolfgang E Berdel; Jan Braess; Thomas Büchner; Philipp Erben; Claudia Haferlach; Torsten Haferlach; Benjamin Hanfstein; Rüdiger Hehlmann; Achim Heinecke; Wolfgang Hiddemann; Wolf-Karsten Hofmann; Heinz A Horst; Karl-Anton Kreuzer; Utz Krug
Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group.
Annals of hematology 2013;92(1):41-52.
2013: Susanne Schnittger; P Staib; H-E Wichmann; T Alpermann; C Eder; A Fasan; V Grossmann; Claudia Haferlach; T Illig; S Jeromin; Wolfgang Kern; N Klopp; Alexander Kohlmann; K-A Kreuzer; Rudolf Peceny; C Schmid; Norbert Schmitz; Torsten Haferlach
ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.
Leukemia 2013;27(1):82-91.
2013: A Fasan; Claudia Haferlach; Torsten Haferlach; Wolfgang Kern; T Alpermann; Susanne Schnittger
A rare but specific subset of adult AML patients can be defined by the cytogenetically cryptic NUP98-NSD1 fusion gene.
Leukemia 2013;27(1):245-8.
2012: Torsten Haferlach
Molecular genetics in myelodysplastic syndromes.
Leukemia research 2012;36(12):1459-62.
2012: Claudia Haferlach; Torsten Haferlach; Wolfgang Kern; Alexander Kohlmann; Sonja Schindela; Ulrike Bacher; Vera Grossmann; Melanie Zenger; Susanne Schnittger
Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.
Genes, chromosomes & cancer 2012;51(12):1079-85.
2012: Susanne Schnittger; Madlen Ulke; Tamara Alpermann; Ulrike Bacher; Frank Dicker; Christiane Eder; Vera Grossmann; Claudia Haferlach; Wolfgang Kern; Alexander Kohlmann; Andreas Kowarsch; Andreas Reiter; Torsten Haferlach
Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases.
Haematologica 2012;97(12):1890-4.
2012: Manja Meggendorfer; Seishi Ogawa; Andreas Roller; Kenichi Yoshida; Tamara Alpermann; Frank Dicker; Christiane Eder; Vera Grossmann; Claudia Haferlach; Torsten Haferlach; Wolfgang Kern; H Phillip Koeffler; Alexander Kohlmann; Susanne Schnittger
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML).
Blood 2012;120(15):3080-8.
2012: Vera Grossmann; Frank Dicker; Christiane Eder; Torsten Haferlach; Wolfgang Kern; Alexander Kohlmann; Karl-Anton Kreuzer; Andreas Roller; Christoph Schmid; Susanne Schnittger; Hubert Serve; Peter Staib; Clemens-Martin Wendtner; Claudia Haferlach
A novel hierarchical prognostic model of AML solely based on molecular mutations.
Blood 2012;120(15):2963-72.
2012: Susanne Schnittger; Wolfgang Kern; Tamara Alpermann; Ulrike Bacher; Claudia Haferlach; Torsten Haferlach
Diversity of the juxtamembrane and TKD1 mutations (exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data.
Genes, chromosomes & cancer 2012;51(10):910-24.
2012: Susanne Schnittger; Wolfgang Kern; Alexander Kohlmann; Tamara Alpermann; Ulrike Bacher; Frank Dicker; Christiane Eder; Vera Grossmann; Claudia Haferlach; Torsten Haferlach
Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow.
Haematologica 2012;97(10):1582-5.
2012: Frauke Bellos; Elena Gouberman; Claudia Haferlach; Torsten Haferlach; Tamara Alpermann; Susanne Schnittger; Wolfgang Kern
Evaluation of flow cytometric assessment of myeloid nuclear differentiation antigen expression as a diagnostic marker for myelodysplastic syndromes in a series of 269 patients.
Cytometry. Part B, Clinical cytometry 2012;82(5):295-304.
2012: Peter Valent; Peter Vandenberghe; Peter F Weller; Michel AROCK; Joseph H Butterfield; Jason Gotlib; Torsten Haferlach; Andrzej Hellmann; Hans-Peter Horny; Amy D Klion; Kristin M Leiferman; Georgia Metzgeroth; Andreas Reiter; Florence Roufosse; Hans-Uwe Simon; Karl Sotlar; Wolfgang R Sperr; Gerald J Gleich
Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes.
The Journal of allergy and clinical immunology 2012;130(3):607-612.e9.
2012: Felicitas Thol; Katharina Wagner; Eva M Weissinger; Martin Wichmann; Haiyang Yun; David Bowen; Gesine Bug; Frederik Damm; Arnold Ganser; Gudrun Göhring; Torsten Haferlach; Wolf-Karsten Hofmann; Jürgen Krauter; Ken Mills; Michael Morgan; Oliver Ottmann; Axel Schambach; Brigitte Schlegelberger; Ann-Kathrin Sonntag; Michael Heuser
Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes.
Annals of hematology 2012;91(8):1221-33.
2012: Ulrike Bacher; Claudia Haferlach; Wolfgang Kern; Susanne Schnittger; Tamara Alpermann; Torsten Haferlach
Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course.
Leukemia research 2012;36(7):826-31.
2012: Ulrike Bacher; Vera Grossmann; Claudia Haferlach; Wolfgang Kern; Alexander Kohlmann; Andreas Kowarsch; Katja Macijewski; Niroshan Nadarajah; Susanne Schnittger; Tamara Alpermann; Torsten Haferlach
Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity.
Blood 2012;119(20):4719-22.
2012: Vera Grossmann; Tamara Alpermann; Valentina Artusi; Ulrike Bacher; Martin Dugas; Torsten Haferlach; Wolfgang Kern; Hans-Ulrich Klein; Alexander Kohlmann; Susanne Schnittger; Claudia Haferlach
EZH2 mutations and their association with PICALM-MLLT10 positive acute leukaemia.
British journal of haematology 2012;157(3):387-90.
2012: Wolfgang Kern; Susanne Schnittger; Tamara Alpermann; Ulrike Bacher; Frank Dicker; Claudia Haferlach; Torsten Haferlach
Frequency and prognostic impact of the aberrant CD8 expression in 5,523 patients with chronic lymphocytic leukemia.
Cytometry. Part B, Clinical cytometry 2012;82(3):145-50.
2012: S Weissmann; A Kowarsch; N Nadarajah; Susanne Schnittger; T Alpermann; Frank Dicker; C Eder; A Fasan; V Grossmann; Claudia Haferlach; Torsten Haferlach; Wolfgang Kern; Alexander Kohlmann
Landscape of TET2 mutations in acute myeloid leukemia.
Leukemia 2012;26(5):934-42.
2012: Peter Valent; Peter Vandenberghe; Peter F Weller; Kristin M Leiferman; Matthias Mayerhofer; Georgia Metzgeroth; Andreas Reiter; Florence Roufosse; Hans-Uwe Simon; Karl Sotlar; Michel AROCK; Bruce S Bochner; Joseph H Butterfield; Sabine Cerny-Reiterer; Gerald J Gleich; Jason Gotlib; Torsten Haferlach; Andrzej Hellmann; Hans-Peter Horny; Amy D Klion
Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field.
Expert review of hematology 2012;5(2):157-76.
2012: Peter Valent; Bruce S Bochner; Torsten Haferlach; Hans-Peter Horny; Andreas Reiter
Controversies and open questions in the definitions and classification of the hypereosinophilic syndromes and eosinophilic leukemias.
Seminars in hematology 2012;49(2):171-81.
2012: Wolfgang Kern; Susanne Schnittger; Tamara Alpermann; Ulrike Bacher; Frank Dicker; Claudia Haferlach; Torsten Haferlach
Monoclonal B-cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early-stage CLL.
British journal of haematology 2012;157(1):86-96.
2012: Claudia Haferlach; Tamara Alpermann; Ulrike Bacher; Wolfgang Kern; Susanne Schnittger; Melanie Zenger; Torsten Haferlach
ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.
Genes, chromosomes & cancer 2012;51(4):328-37.
2012: Claudia Haferlach; V Grossmann; Wolfgang Kern; A Kohlmann; S Schindela; Susanne Schnittger; Torsten Haferlach
Deletion of the tumor-suppressor gene NF1 occurs in 5% of myeloid malignancies and is accompanied by a mutation in the remaining allele in half of the cases.
Leukemia 2012;26(4):834-9.
2012: Susanne Schnittger; Madlen Ulke; Nicole Wendland; Ulrike Bacher; Frank Dicker; Vera Grossmann; Claudia Haferlach; Torsten Haferlach; Wolfgang Kern
Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia.
Blood 2012;119(13):3151-4.
2012: Claudia Haferlach; Tamara Alpermann; Jörg Chromik; Heinz-Gert Höffkes; Wolfgang Kern; Karl-Anton Kreuzer; Hermann Josef Pielken; Christoph Schmid; Susanne Schnittger; Torsten Haferlach
Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype.
Blood 2012;119(9):2122-5.
2012: Alexander Kohlmann; Vera Grossmann; Torsten Haferlach
Integration of next-generation sequencing into clinical practice: are we there yet?
Seminars in oncology 2012;39(1):26-36.
2011: Susanne Schnittger; Wolfgang Kern; Tamara Alpermann; Ulrike Bacher; Claudia Haferlach; Torsten Haferlach
Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA.
Haematologica 2011;96(12):1799-807.
2011: Christoph Walz; Michael Ritter; Joannah Score; Nick Telford; Adrian Bloor; Nicholas C P Cross; Philipp Erben; Stefan Gesk; Claudia Haferlach; Torsten Haferlach; Andreas Hochhaus; Wolf-Karsten Hofmann; Georgia Metzgeroth; Andreas Reiter
Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3.
Blood 2011;118(8):2239-42.
2011: Susanne Schnittger; Wolfgang Kern; T Alpermann; Ulrike Bacher; Claudia Haferlach; Torsten Haferlach
Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia.
Leukemia 2011;25(8):1297-304.
2011: Ulrike Bacher; M Dugas; C Haferlach; W Kern; H-U Klein; A Kohlmann; S Schnittger; T Alpermann; Torsten Haferlach
Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics.
Leukemia 2011;25(8):1361-4.
2011: Maria Kleppe; Laurent Knoops; Elizabeth Macintyre; Jules P P Meijerink; Nicole Mentens; François Sigaux; Jean Soulier; Marco Tartaglia; Peter Vandenberghe; Vahid Asnafi; Stefan Constantinescu; Robin Foa; Torsten Haferlach; Tekla Hornakova; Jan Cools
PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia.
Blood 2011;117(26):7090-8.
2011: Ulrike Bacher; Maximilian Christopeit; Bettina Wiedemann; Ivo Leuschner; Torsten Haferlach; Matthias Choschzick
Ganglioneuroblastoma infiltrating the bone marrow in an adult.
British journal of haematology 2011;153(5):544.
2011: V Grossmann; A Kohlmann; C Eder; Claudia Haferlach; Wolfgang Kern; N C P Cross; Torsten Haferlach; Susanne Schnittger
Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance.
Leukemia 2011;25(5):877-9.
2011: Claudia Haferlach; Ulrike Bacher; Torsten Haferlach; Frank Dicker; T Alpermann; Wolfgang Kern; Susanne Schnittger
The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML.
Leukemia 2011;25(5):874-7.
2011: Hans-Ulrich Klein; Christoph Bartenhagen; Alexander Kohlmann; Vera Grossmann; Christian Ruckert; Torsten Haferlach; Martin Dugas
R453Plus1Toolbox: an R/Bioconductor package for analyzing Roche 454 Sequencing data.
Bioinformatics (Oxford, England) 2011;27(8):1162-3.
2011: Ulrike Bacher; Torsten Haferlach; Hans Kreipe; Susanne Schnittger; Nicolaus Kröger
Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia.
British journal of haematology 2011;153(2):149-67.
2011: V Grossmann; A Kohlmann; H-U Klein; S Schindela; Susanne Schnittger; Frank Dicker; M Dugas; Wolfgang Kern; Torsten Haferlach; Claudia Haferlach
Targeted next-generation sequencing detects point mutations, insertions, deletions and balanced chromosomal rearrangements as well as identifies novel leukemia-specific fusion genes in a single procedure.
Leukemia 2011;25(4):671-80.
2011: Susanne Schnittger; Ulrike Bacher; Claudia Haferlach; T Alpermann; Frank Dicker; J Sundermann; Wolfgang Kern; Torsten Haferlach
Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.
Leukemia 2011;25(4):615-21.
2011: J Flach; Frank Dicker; Susanne Schnittger; S Schindela; A Kohlmann; Torsten Haferlach; Wolfgang Kern; Claudia Haferlach
An accumulation of cytogenetic and molecular genetic events characterizes the progression from MDS to secondary AML: an analysis of 38 paired samples analyzed by cytogenetics, molecular mutation analysis and SNP microarray profiling.
Leukemia 2011;25(4):713-8.
2011: Francesco Passamonti; Chiara Elena; Susanne Schnittger; Radek C Skoda; Anthony R Green; François Girodon; Jean-Jacques Kiladjian; Mary Frances McMullin; Marco Ruggeri; Carles Besses; Alessandro M Vannucchi; Eric Lippert; Heinz Gisslinger; Elisa Rumi; Thomas Lehmann; Christina A Ortmann; Daniela Pietra; Cristiana Pascutto; Torsten Haferlach; Mario Cazzola
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.
Blood 2011;117(10):2813-6.
2011: Vera Grossmann; Susanne Schnittger; Sonja Schindela; Hans-Ulrich Klein; Christiane Eder; Martin Dugas; Wolfgang Kern; Torsten Haferlach; Claudia Haferlach; Alexander Kohlmann
Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technology.
The Journal of molecular diagnostics : JMD 2011;13(2):129-36.
2011: Ulrike Bacher; Torsten Haferlach; Tamara Alpermann; Melanie Zenger; Andreas Hochhaus; Dietrich W Beelen; Michael Uppenkamp; Mathias Rummel; Wolfgang Kern; Susanne Schnittger; Claudia Haferlach
Subclones with the t(9;22)/BCR-ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations.
British journal of haematology 2011;152(6):713-20.
2011: V Grossmann; A Kohlmann; M Zenger; S Schindela; C Eder; S Weissmann; Susanne Schnittger; Wolfgang Kern; M C Müller; A Hochhaus; Torsten Haferlach; Claudia Haferlach
A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases.
Leukemia 2011;25(3):557-60.
2011: Susanne Schnittger; Frank Dicker; Wolfgang Kern; Nicole Wendland; Jana Sundermann; Tamara Alpermann; Claudia Haferlach; Torsten Haferlach
RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis.
Blood 2011;117(8):2348-57.
2011: Guido Marcucci; Torsten Haferlach; Hartmut Döhner
Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):475-86.
2011: Brunangelo Falini; Maria Paola Martelli; Niccolò Bolli; Paolo Sportoletti; Arcangelo Liso; Enrico Tiacci; Torsten Haferlach
Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?
Blood 2011;117(4):1109-20.
2011: Ulrike Bacher; Torsten Haferlach; Boris Fehse; Susanne Schnittger; Nicolaus Kröger
Minimal residual disease diagnostics and chimerism in the post-transplant period in acute myeloid leukemia.
TheScientificWorldJournal 2011;11():310-9.
2011: Wolfgang Kern; Ulrike Bacher; Claudia Haferlach; Susanne Schnittger; Torsten Haferlach
Acute monoblastic/monocytic leukemia and chronic myelomonocytic leukemia share common immunophenotypic features but differ in the extent of aberrantly expressed antigens and amount of granulocytic cells.
Leukemia & lymphoma 2011;52(1):92-100.
2011: Sandra Heesch; Isabelle Bartram; Martin Neumann; Jana Reins; Maximilian Mossner; Cornelia Schlee; Andrea Stroux; Torsten Haferlach; Nicola Goekbuget; Dieter Hoelzer; Wolf-Karsten Hofmann; Eckhard Thiel; Claudia D Baldus
Expression of IGFBP7 in acute leukemia is regulated by DNA methylation.
Cancer science 2011;102(1):253-9.
2011: Ulrike Bacher; Torsten Haferlach; Tamara Alpermann; Wolfgang Kern; Susanne Schnittger; Claudia Haferlach
Several lymphoma-specific genetic events in parallel can be found in mature B-cell neoplasms.
Genes, chromosomes & cancer 2011;50(1):43-50.
2011: Susanne Schnittger; Ulrike Bacher; Christiane Eder; Peter Lohse; Claudia Haferlach; Wolfgang Kern; Torsten Haferlach
A copy number repeat polymorphism in the transactivation domain of the CEPBA gene is possibly associated with a protective effect against acquired CEBPA mutations: an analysis in 1135 patients with AML and 187 healthy controls.
Experimental hematology 2011;39(1):87-94.
2010: Susanne Schnittger; Claudia Haferlach; Madlen Ulke; Tamara Alpermann; Wolfgang Kern; Torsten Haferlach
IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.
Blood 2010;116(25):5486-96.
2010: Utz Krug; Christoph Röllig; Anja Koschmieder; Achim Heinecke; Maria Cristina Sauerland; Markus Schaich; Christian Thiede; Michael Kramer; Jan Braess; Karsten Spiekermann; Torsten Haferlach; Claudia Haferlach; Steffen Koschmieder; Christian Rohde; Hubert Serve; Bernhard Wörmann; Wolfgang Hiddemann; Gerhard Ehninger; Wolfgang E Berdel; Thomas Büchner; Carsten Müller-Tidow
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.
Lancet 2010;376(9757):2000-8.
2010: Ulrike Bacher; Torsten Haferlach; Wolfgang Kern; Tamara Alpermann; Susanne Schnittger; Claudia Haferlach
Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma.
Cancer genetics and cytogenetics 2010;203(2):169-75.
2010: Ulrike Bacher; Alexander Kohlmann; Torsten Haferlach
Gene expression profiling for diagnosis and therapy in acute leukaemia and other haematologic malignancies.
Cancer treatment reviews 2010;36(8):637-46.
2010: Ulrike Bacher; Torsten Haferlach; Tamara Alpermann; Melanie Zenger; Nicolaus Kröger; Dietrich W Beelen; Wolfgang Kern; Susanne Schnittger; Claudia Haferlach
Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2010;16(12):1649-57.
2010: Gina Zini; Barbara Bain; Peter Bettelheim; José Cortez; Giuseppe d'Onofrio; Edgar Faber; Torsten Haferlach; Petra Kacirkova; Krzysztof Lewandowski; Estella Matutes; Marc Maynadié; John Meletis; Bodil L Petersen; Anna Porwit; Evangelos Terpos; Andrée Tichelli; Teresa Vallespí; Soledad Woessner; John Bennett; Marie C Bene
A European consensus report on blood cell identification: terminology utilized and morphological diagnosis concordance among 28 experts from 17 countries within the European LeukemiaNet network WP10, on behalf of the ELN Morphology Faculty.
British journal of haematology 2010;151(4):359-64.
2010: Ulrike Bacher; Susanne Schnittger; Torsten Haferlach
Molecular genetics in acute myeloid leukemia.
Current opinion in oncology 2010;22(6):646-55.
2010: Miriam Miesner; Claudia Haferlach; Ulrike Bacher; Tamara Weiss; Katja Macijewski; Alexander Kohlmann; Hans-Ulrich Klein; Martin Dugas; Wolfgang Kern; Susanne Schnittger; Torsten Haferlach
Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC).
Blood 2010;116(15):2742-51.
2010: Lena Reindl; Ulrike Bacher; Frank Dicker; Tamara Alpermann; Wolfgang Kern; Susanne Schnittger; Torsten Haferlach; Claudia Haferlach
Biological and clinical characterization of recurrent 14q deletions in CLL and other mature B-cell neoplasms.
British journal of haematology 2010;151(1):25-36.
2010: Susanne Schnittger; Ulrike Bacher; Frank Dicker; Wolfgang Kern; Tamara Alpermann; Torsten Haferlach; Claudia Haferlach
Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML.
Genes, chromosomes & cancer 2010;49(10):910-8.
2010: Wolfgang Kern; Claudia Haferlach; Susanne Schnittger; Torsten Haferlach
Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data.
Cancer 2010;116(19):4549-63.
2010: Wolfgang Kern; Ulrike Bacher; Claudia Haferlach; Susanne Schnittger; Torsten Haferlach
The role of multiparameter flow cytometry for disease monitoring in AML.
Best practice & research. Clinical haematology 2010;23(3):379-90.
2010: Claudia Haferlach; Frank Dicker; Tamara Weiss; Susanne Schnittger; Christian Beck; Albert Grote-Metke; Daniel Oruzio; Wolfgang Kern; Torsten Haferlach
Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters.
Genes, chromosomes & cancer 2010;49(9):851-9.
2010: Ryoko Okamoto; Seishi Ogawa; Daniel Nowak; Norihiko Kawamata; Tadayuki Akagi; Motohiro Kato; Masashi Sanada; Tamara Weiss; Claudia Haferlach; Martin Dugas; Christian Ruckert; Torsten Haferlach; H Phillip Koeffler
Genomic profiling of adult acute lymphoblastic leukemia by single nucleotide polymorphism oligonucleotide microarray and comparison to pediatric acute lymphoblastic leukemia.
Haematologica 2010;95(9):1481-8.
2010: Alexander Kohlmann; Vera Grossmann; Hans-Ulrich Klein; Sonja Schindela; Tamara Weiss; Beray Kazak; Frank Dicker; Susanne Schnittger; Martin Dugas; Wolfgang Kern; Claudia Haferlach; Torsten Haferlach
Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3858-65.
2010: Ulrike Bacher; Torsten Haferlach; Susanne Schnittger; Tamara Weiss; Oswald Burkhard; Britta Bechtel; Wolfgang Kern; Claudia Haferlach
Detection of a t(4;14)(p16;q32) in two cases of lymphoma showing both the immunophenotype of chronic lymphocytic leukemia.
Cancer genetics and cytogenetics 2010;200(2):170-4.
2010: Ulrike Bacher; Claudia Haferlach; Susanne Schnittger; Alexander Kohlmann; Wolfgang Kern; Torsten Haferlach
Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies.
Annals of hematology 2010;89(7):643-52.
2010: Maria Kleppe; Idoya Lahortiga; Tiama El Chaar; Kim De Keersmaecker; Nicole Mentens; Carlos Graux; Katrien Van Roosbroeck; Adolfo Ferrando; Anton W Langerak; Jules P P Meijerink; François Sigaux; Torsten Haferlach; Iwona Wlodarska; Peter Vandenberghe; Jean Soulier; Jan Cools
Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia.
Nature genetics 2010;42(6):530-5.
2010: A Kohlmann; L Bullinger; C Thiede; M Schaich; Susanne Schnittger; K Döhner; M Dugas; H-U Klein; H Döhner; G Ehninger; Torsten Haferlach
Gene expression profiling in AML with normal karyotype can predict mutations for molecular markers and allows novel insights into perturbed biological pathways.
Leukemia 2010;24(6):1216-20.
2010: Georgios Papakonstantinou; Helmut Loeffler; Torsten Haferlach; Wolfram Brugger
Severe idiopathic erythroblastic synartesis: successful treatment with the anti-CD20 monoclonal antibody rituximab.
European journal of haematology 2010;84(6):547-9.
2010: Torsten Haferlach; Alexander Kohlmann; Lothar Wieczorek; Giuseppe Basso; Geertruy Te Kronnie; Marie-Christine Béné; John De Vos; Jesus M Hernández; Wolf-Karsten Hofmann; Ken I Mills; Amanda Gilkes; Sabina Chiaretti; Sheila A Shurtleff; Thomas J Kipps; Laura Z Rassenti; Allen E Yeoh; Peter R Papenhausen; Wei-Min Liu; P Mickey Williams; Robin Foà
Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(15):2529-37.
2010: Brunangelo Falini; Katja Macijewski; Tamara Weiss; Ulrike Bacher; Susanne Schnittger; Wolfgang Kern; Alexander Kohlmann; Hans-Ulrich Klein; Marco Vignetti; Alfonso Piciocchi; Paola Fazi; Maria Paola Martelli; Antonella Vitale; Stefano Pileri; Miriam Miesner; Antonella Santucci; Claudia Haferlach; Franco Mandelli; Torsten Haferlach
Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).
Blood 2010;115(18):3776-86.
2010: Andrea Kühnl; Nicola Gökbuget; Andrea Stroux; Thomas Burmeister; Martin Neumann; Sandra Heesch; Torsten Haferlach; Dieter Hoelzer; Wolf-Karsten Hofmann; Eckhard Thiel; Claudia D Baldus
High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia.
Blood 2010;115(18):3737-44.
2010: Nils Thoennissen; Utz O Krug; Dhong Hyun Tony Lee; Norihiko Kawamata; Gabriela B Iwanski; Terra Lasho; Tamara Weiss; Daniel Nowak; Maya Koren-Michowitz; Motohiro Kato; Masashi Sanada; Lee-Yung Shih; Arnon Nagler; Sophie D Raynaud; Carsten Müller-Tidow; Ruben Mesa; Torsten Haferlach; D Gary Gilliland; Ayalew Tefferi; Seishi Ogawa; H Phillip Koeffler
Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms.
Blood 2010;115(14):2882-90.
2010: Johanna Flach; Frank Dicker; Susanne Schnittger; Alexander Kohlmann; Torsten Haferlach; Claudia Haferlach
Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis.
Haematologica 2010;95(3):518-9.
2010: Daniel Nowak; Seishi Ogawa; Markus Müschen; Motohiro Kato; Norihiko Kawamata; Antonie Meixel; Verena Nowak; Han S Kim; Sharon Kang; Ronald Paquette; Mi-Sook Chang; Nils H Thoennissen; Nils H Thoenissen; Max Mossner; Wolf-Karsten Hofmann; Alexander Kohlmann; Tamara Weiss; Torsten Haferlach; Claudia Haferlach; H Phillip Koeffler
SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations.
Blood 2010;115(5):1049-53.
2010: Hannes Wandt; Torsten Haferlach; Christian Thiede; Gerhard Ehninger
WHO classification of myeloid neoplasms and leukemia.
Blood 2010;115(3):748-9; author reply 749-50.
2010: Ulrike Bacher; Claudia Haferlach; Nicolaus Kröger; Susanne Schnittger; Wolfgang Kern; Bettina Wiedemann; Axel Rolf Zander; Torsten Haferlach
Diagnostic tools in the indications for allogeneic stem cell transplantation in myelodysplastic syndromes.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2010;16(1):1-11.
2009: Eva Lengfelder; Claudia Haferlach; Susanne Saussele; Torsten Haferlach; Beate Schultheis; S Schnittger; Wolf-Dieter Ludwig; Peter Staib; Carlo Aul; A Grüneisen; W Kern; A Reichle; Hubert Serve; Wolfgang E Berdel; J Braess; K Spiekermann; Bernhard Wörmann; Maria Cristina Sauerland; Achim Heinecke; Wolfgang Hiddemann; Rüdiger Hehlmann; Thomas Büchner
High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG.
Leukemia 2009;23(12):2248-58.
2009: Ulrike Bacher; Susanne Schnittger; Wolfgang Kern; Tamara Weiss; Torsten Haferlach; Claudia Haferlach
Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
Annals of hematology 2009;88(12):1207-13.
2009: Wolfgang Kern; Frank Dicker; Susanne Schnittger; Claudia Haferlach; Torsten Haferlach
Correlation of flow cytometrically determined expression of ZAP-70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemia.
Cytometry. Part B, Clinical cytometry 2009;76(6):385-93.
2009: Ulrike Bacher; Torsten Haferlach; Wolfgang Kern; Tamara Weiss; Susanne Schnittger; Claudia Haferlach
The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes.
Cancer 2009;115(19):4524-32.
2009: Claudia Haferlach; Cristina Mecucci; Susanne Schnittger; Alexander Kohlmann; Marco Mancini; Antonio Cuneo; Nicoletta Testoni; Giovanna Rege-Cambrin; Antonella Santucci; Marco Vignetti; Paola Fazi; Maria Paola Martelli; Torsten Haferlach; Brunangelo Falini
AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features.
Blood 2009;114(14):3024-32.
2009: Reinhold Munker; Mary Lowery Nordberg; Diana Veillon; B Jill Williams; Anthony Roggero; Wolfgang Kern; Frank Dicker; Torsten Haferlach
Characterization of a new myeloid leukemia cell line with normal cytogenetics (CG-SH).
Leukemia research 2009;33(10):1405-8.
2009: Susanne Schnittger; Wolfgang Kern; Claudia Tschulik; Tamara Weiss; Frank Dicker; Brunangelo Falini; Claudia Haferlach; Torsten Haferlach
Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.
Blood 2009;114(11):2220-31.
2009: Susanne Schnittger; Ulrike Bacher; Wolfgang Kern; Claudia Tschulik; Tamara Weiss; Claudia Haferlach; Torsten Haferlach
RQ-PCR based WT1 expression in comparison to BCR-ABL quantification can predict Philadelphia negative clonal evolution in patients with imatinib-treated chronic myeloid leukaemia.
British journal of haematology 2009;146(6):665-8.
2009: Ken I Mills; Alexander Kohlmann; P Mickey Williams; Lothar Wieczorek; Wei-min Liu; Rachel Li; Wen Wei; David T Bowen; Helmut Loeffler; Jesus M Hernandez; Wolf-Karsten Hofmann; Torsten Haferlach
Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome.
Blood 2009;114(5):1063-72.
2009: Peter Valent; Wolf-Karsten Hofmann; Guntram Büsche; Karl Sotlar; Hans-Peter Horny; Detlef Haase; Torsten Haferlach; Wolfgang Kern; Peter Bettelheim; Christian Baumgartner; Wolfgang R Sperr; Thomas Nösslinger; Friedrich Wimazal; Aristoteles A Giagounidis; Michael Lübbert; Otto Krieger; Hans-Jochem Kolb; Reinhard Stauder; Michael Pfeilstöcker; Norbert Gattermann; Christa Fonatsch; Carlo Aul; Ulrich Germing
Meeting report: Vienna 2008 Workshop of the German-Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes.
Annals of hematology 2009;88(7):607-11.
2009: Ulrike Bacher; Alexander Kohlmann; Claudia Haferlach; Torsten Haferlach
Gene expression profiling in acute myeloid leukaemia (AML).
Best practice & research. Clinical haematology 2009;22(2):169-80.
2009: Ulrike Bacher; Alexander Kohlmann; Torsten Haferlach
Current status of gene expression profiling in the diagnosis and management of acute leukaemia.
British journal of haematology 2009;145(5):555-68.
2009: Andrea Zatkova; Sylvia Merk; Melanie Wendehack; Martin Bilban; Eva Maria Muzik; Artur Muradyan; Claudia Haferlach; Torsten Haferlach; Katharina Wimmer; Christa Fonatsch; Reinhard Ullmann
AML/MDS with 11q/MLL amplification show characteristic gene expression signature and interplay of DNA copy number changes.
Genes, chromosomes & cancer 2009;48(6):510-20.
2009: Ulrike Bacher; Alexander Kohlmann; Torsten Haferlach
Perspectives of gene expression profiling for diagnosis and therapy in haematological malignancies.
Briefings in functional genomics & proteomics 2009;8(3):184-93.
2009: Torsten Haferlach; A Kohlmann; H-U Klein; C Ruckert; M Dugas; P M Williams; Wolfgang Kern; Susanne Schnittger; Ulrike Bacher; H Löffler; Claudia Haferlach
AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features.
Leukemia 2009;23(5):934-43.
2009: Frank Breitenbuecher; Susanne Schnittger; Rebekka Grundler; Boyka Markova; Birgit Carius; Alexandra Brecht; Justus Duyster; Torsten Haferlach; Christoph Huber; Thomas Fischer
Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor.
Blood 2009;113(17):4074-7.
2009: Peter Bojko; Wolfgang Abenhardt; Susanne Schnittger; Torsten Haferlach
Mutations in the JAK2 and MPL genes and their correlation to clinical parameters in patients with chronic myeloproliferative disease.
Onkologie 2009;32(4):191-5.
2009: Susanne Schnittger; Ulrike Bacher; Claudia Haferlach; Thomas Geer; Peter Müller; Johann Mittermüller; Petro Petrides; Rudolf Schlag; Reiner Sandner; Johannes Selbach; Hans Rainer Slawik; Hans Werner Tessen; Jürgen Wehmeyer; Wolfgang Kern; Torsten Haferlach
Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera.
Haematologica 2009;94(3):414-8.
2009: Tadayuki Akagi; Seishi Ogawa; Martin Dugas; Norihiko Kawamata; Go Yamamoto; Yasuhito Nannya; Masashi Sanada; Carl W Miller; Amanda Yung; Susanne Schnittger; Torsten Haferlach; Claudia Haferlach; H Phillip Koeffler
Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype.
Haematologica 2009;94(2):213-23.
2009: Hans-Ulrich Klein; Christian Ruckert; Alexander Kohlmann; Lars Bullinger; Christian Thiede; Torsten Haferlach; Martin Dugas
Quantitative comparison of microarray experiments with published leukemia related gene expression signatures.
BMC bioinformatics 2009;10():422.
2009: Ulrike Bacher; Susanne Schnittger; Claudia Haferlach; Torsten Haferlach
Molecular diagnostics in acute leukemias.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2009;47(11):1333-41.
2009: Torsten Haferlach; Ulrike Bacher; Alexander Kohlmann; Claudia Haferlach
Discussion of the applicability of microarrays: profiling of leukemias.
Methods in molecular biology (Clifton, N.J.) 2009;509():15-33.
2009: Thomas Büchner; Wolfgang E Berdel; Claudia Haferlach; Torsten Haferlach; Susanne Schnittger; Carsten Müller-Tidow; Jan Braess; Karsten Spiekermann; Joachim Kienast; Peter Staib; Andreas Grüneisen; Wolfgang Kern; Albrecht Reichle; Georg Maschmeyer; Carlo Aul; Eva Lengfelder; Maria Cristina Sauerland; Achim Heinecke; Bernhard Wörmann; Wolfgang Hiddemann
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(1):61-9.
2009: Susanne Schnittger; Ulrike Bacher; Claudia Haferlach; Dietrich Beelen; Peter Bojko; Dieter Bürkle; Robert Dengler; Andrea Distelrath; Michael Eckart; Robert Eckert; Stefan Fries; Jan Knoblich; Georg Köchling; Hans-Peter Laubenstein; Petro Petrides; Manfred Planker; Rudolf Pihusch; Rudolf Weide; Wolfgang Kern; Torsten Haferlach
Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis.
Haematologica 2009;94(1):141-4.
2009: Frank Dicker; H Herholz; Susanne Schnittger; A Nakao; N Patten; L Wu; Wolfgang Kern; Torsten Haferlach; Claudia Haferlach
The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype.
Leukemia 2009;23(1):117-24.
2008: Tobias Berg; Manfred Fliegauf; Jan Burger; Martin S Staege; Shaohua Liu; Natalia Martinez; Olaf Heidenreich; Stefan Burdach; Torsten Haferlach; Milton H Werner; Michael Lübbert
Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETO.
Haematologica 2008;93(11):1728-33.
2008: Alexander Kohlmann; Elisabeth Haschke-Becher; Barbara Wimmer; Ariana Huber-Wechselberger; Sandrine Meyer-Monard; Heike Huxol; Uwe Siegler; Michel Rossier; Thomas Matthes; Michela Rebsamen; Alberto Chiappe; Adeline Diemand; Sonja Rauhut; Andrea Johnson; Wei-Min Liu; P Mickey Williams; Lothar Wieczorek; Torsten Haferlach
Intraplatform reproducibility and technical precision of gene expression profiling in 4 laboratories investigating 160 leukemia samples: the DACH study.
Clinical chemistry 2008;54(10):1705-15.
2008: Alexander Kohlmann; Thomas Kipps; Laura Z Rassenti; James R Downing; Sheila A Shurtleff; Ken Mills; Amanda F Gilkes; Wolf-Karsten Hofmann; Giuseppe Basso; Marta Campo Dell'orto; Robin Foà; Sabina Chiaretti; John De Vos; Sonja Rauhut; Peter R Papenhausen; Jesus M Hernández; Eva Lumbreras; Allen E Yeoh; Evelyn S Koay; Rachel Li; Wei-Min Liu; Paul M Williams; Lothar Wieczorek; Torsten Haferlach
An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase.
British journal of haematology 2008;142(5):802-7.
2008: Arcangelo Liso; Filippo Castiglione; Antonio Cappuccio; Fabrizio Stracci; Richard F Schlenk; Sergio Amadori; Christian Thiede; Susanne Schnittger; Peter J M Valk; Konstanze Döhner; Massimo F Martelli; Markus Schaich; Jürgen Krauter; Arnold Ganser; Maria P Martelli; Niccolò Bolli; Bob Löwenberg; Torsten Haferlach; Gerhard Ehninger; Franco Mandelli; Hartmut Döhner; Franziska Michor; Brunangelo Falini
A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1).
Haematologica 2008;93(8):1219-26.
2008: Ulrike Bacher; Axel R Zander; Torsten Haferlach; Susanne Schnittger; Boris Fehse; Nicolaus Kröger
Minimal residual disease diagnostics in myeloid malignancies in the post transplant period.
Bone marrow transplantation 2008;42(3):145-57.
2008: Claudia Haferlach; Frank Dicker; H Herholz; Susanne Schnittger; Wolfgang Kern; Torsten Haferlach
Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype.
Leukemia 2008;22(8):1539-41.
2008: Brunangelo Falini; Maria Paola Martelli; Cristina Mecucci; Arcangelo Liso; Niccolò Bolli; Barbara Bigerna; Alessandra Pucciarini; Stefano Pileri; Giovanna Meloni; Massimo F Martelli; Torsten Haferlach; Susanne Schnittger
Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice.
Haematologica 2008;93(5):775-9.
2008: Ramiro Garzon; Michela Garofalo; Maria Paola Martelli; Roger Briesewitz; Lisheng Wang; Cecilia Fernandez-Cymering; Stefano Volinia; Chang-gong liu; Susanne Schnittger; Torsten Haferlach; Arcangelo Liso; Daniela Diverio; Marco Mancini; Giovanna Meloni; Robin Foa; Massimo F Martelli; Cristina Mecucci; Carlo M Croce; Brunangelo Falini
Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(10):3945-50.
2008: Brunangelo Falini; Cristina Mecucci; Giuseppe Saglio; Francesco Lo Coco; Daniela Diverio; Patrick Brown; Fabrizio Pane; Marco Mancini; Maria Paola Martelli; Stefano Pileri; Torsten Haferlach; Claudia Haferlach; Susanne Schnittger
NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia.
Haematologica 2008;93(3):439-42.
2008: Ulrike Bacher; Claudia Haferlach; Wolfgang Kern; Torsten Haferlach; Susanne Schnittger
Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.
Blood 2008;111(5):2527-37.
2008: Susanne Schnittger; Ulrike Bacher; Claudia Haferlach; R Dengler; A Kröber; Wolfgang Kern; Torsten Haferlach
Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis.
Leukemia 2008;22(2):453-5.
2008: Wolfgang Kern; Claudia Haferlach; Torsten Haferlach; Susanne Schnittger
Monitoring of minimal residual disease in acute myeloid leukemia.
Cancer 2008;112(1):4-16.
2008: Torsten Haferlach; Ulrike Bacher; Wolfgang Kern; Susanne Schnittger; Claudia Haferlach
The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers.
Annals of hematology 2008;87(1):1-10.
2007: Claudia Haferlach; Frank Dicker; Susanne Schnittger; Wolfgang Kern; Torsten Haferlach
Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping.
Leukemia 2007;21(12):2442-51.
2007: Martin Weisser; Claudia Haferlach; Torsten Haferlach; Susanne Schnittger
Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3) (q21;q26) positive AML.
Leukemia & lymphoma 2007;48(11):2145-51.
2007: Torsten Haferlach; Ulrike Bacher; Wolfgang Kern; Susanne Schnittger; Claudia Haferlach
[Diagnostic algorithm in chronic myeloproliferative diseases (CMPD)].
Medizinische Klinik (Munich, Germany : 1983) 2007;102(9):770-7.
2007: Frank Dicker; Claudia Haferlach; Wolfgang Kern; Torsten Haferlach; Susanne Schnittger
Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia.
Blood 2007;110(4):1308-16.
2007: Martin Weisser; Claudia Haferlach; Torsten Haferlach; Susanne Schnittger
Feasibility of using the combined MDS-EVI1/EVI1 gene expression as an alternative molecular marker in acute myeloid leukemia: a report of four cases.
Cancer genetics and cytogenetics 2007;177(1):64-9.
2007: Katharina Tschoep; Alexander Kohlmann; Marcus Schlemmer; Torsten Haferlach; Rolf Issels
Gene expression profiling in sarcomas.
Critical reviews in oncology/hematology 2007;63(2):111-24.
2007: Susanne Schnittger; Ulrike Bacher; Wolfgang Kern; Torsten Haferlach; Claudia Haferlach
JAK2V617F as progression marker in CMPD and as cooperative mutation in AML with trisomy 8 and t(8;21): a comparative study on 1103 CMPD and 269 AML cases.
Leukemia 2007;21(8):1843-5.
2007: Ulrike Bacher; Torsten Haferlach; Wolfgang Kern; Claudia Haferlach; Susanne Schnittger
A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia.
Haematologica 2007;92(6):744-52.
2007: Georgia Metzgeroth; Christoph Walz; Joannah Score; R Siebert; S Schnittger; Claudia Haferlach; H Popp; Torsten Haferlach; Philipp Erben; J Mix; Martin C Müller; H Beneke; L Müller; F Del Valle; Walter Aulitzky; G Wittkowsky; Norbert Schmitz; C Schulte; K Müller-Hermelink; E Hodges; S J Whittaker; F Diecker; H Döhner; P Schuld; Rüdiger Hehlmann; Andreas Hochhaus; Nicholas C P Cross; Andreas Reiter
Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.
Leukemia 2007;21(6):1183-8.
2007: Peter Valent; Hans-Peter Horny; John M Bennett; Christa Fonatsch; Ulrich Germing; Peter Greenberg; Torsten Haferlach; Detlef Haase; Hans-Jochen Kolb; Otto Krieger; Michael R Loken; Arjan van de Loosdrecht; Kiyoyuki Ogata; Alberto Orfao; Michael Pfeilstöcker; Björn Rüter; Wolfgang R Sperr; Reinhard Stauder; Denise A Wells
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference.
Leukemia research 2007;31(6):727-36.
2007: Ulrike Bacher; Torsten Haferlach; Wolfgang Kern; Hans-Detlev Harich; Susanne Schnittger; Claudia Haferlach
A case of chronic myeloproliferative syndrome followed by precursor T-cell acute lymphoblastic leukemia.
Cancer genetics and cytogenetics 2007;175(1):52-6.
2007: Torsten Haferlach; Ulrike Bacher; Wolfgang Kern; Susanne Schnittger; Claudia Haferlach
Diagnostic pathways in acute leukemias: a proposal for a multimodal approach.
Annals of hematology 2007;86(5):311-27.
2007: Hannes Herholz; Wolfgang Kern; Susanne Schnittger; Torsten Haferlach; Frank Dicker; Claudia Haferlach
Translocations as a mechanism for homozygous deletion of 13q14 and loss of the ATM gene in a patient with B-cell chronic lymphocytic leukemia.
Cancer genetics and cytogenetics 2007;174(1):57-60.
2007: Susanne Schnittger; Ulrike Bacher; Claudia Haferlach; Wolfgang Kern; Torsten Haferlach
Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients.
Leukemia 2007;21(4):725-31.
2007: Torsten Haferlach; Ulrike Bacher; Claudia Haferlach; Wolfgang Kern; Susanne Schnittger
Insight into the molecular pathogenesis of myeloid malignancies.
Current opinion in hematology 2007;14(2):90-7.
2007: Torsten Haferlach; A Kohlmann; Ulrike Bacher; Susanne Schnittger; Claudia Haferlach; Wolfgang Kern
Gene expression profiling for the diagnosis of acute leukaemia.
British journal of cancer 2007;96(4):535-40.
2007: Susanne Schnittger; Ulrike Bacher; Wolfgang Kern; Claudia Haferlach; Torsten Haferlach
JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML.
Leukemia 2007;21(1):183-4.
2006: Martin Weisser; Wolfgang Kern; Claudia Schoch; Claudia Tschulik; Wolfgang Hiddemann; Torsten Haferlach; Susanne Schnittger
Reverse transcriptase-polymerase chain reaction based quantification of the combined MDS-EVI1/EVI1 gene in acute myeloid leukemia.
Leukemia & lymphoma 2006;47(12):2645-7.
2006: Claudia Schoch; Alexander Kohlmann; Martin Dugas; Wolfgang Kern; Susanne Schnittger; Torsten Haferlach
Impact of trisomy 8 on expression of genes located on chromosome 8 in different AML subgroups.
Genes, chromosomes & cancer 2006;45(12):1164-8.
2006: Torsten Haferlach; Ulrike Bacher; Alexander Kohlmann; Susanne Schnittger; Wolfgang Kern; Claudia Haferlach
[Microarrays and gene expression profiling for the diagnosis in leukemia. From research studies to routine application].
Medizinische Klinik (Munich, Germany : 1983) 2006;101(11):908-14.
2006: Wolfgang Kern; Alexander Kohlmann; Claudia Schoch; Susanne Schnittger; Torsten Haferlach
Comparison of mRNA abundance quantified by gene expression profiling and percentage of positive cells using immunophenotyping for diagnostic antigens in acute and chronic leukemias.
Cancer 2006;107(10):2401-7.
2006: Elise Chapiro; Eric Delabesse; Vahid Asnafi; Corinne Millien; Frédéric Davi; Elizabeth Nugent; Kheira Beldjord; Torsten Haferlach; David Grimwade; Elizabeth Macintyre
Expression of T-lineage-affiliated transcripts and TCR rearrangements in acute promyelocytic leukemia: implications for the cellular target of t(15;17).
Blood 2006;108(10):3484-93.
2006: Frank Dicker; Susanne Schnittger; Torsten Haferlach; Wolfgang Kern; Claudia Schoch
Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression.
Blood 2006;108(9):3152-60.
2006: Susanne Saussele; K Adam; Andreas Hochhaus; marie bene; Thomas Büchner; A Burnett; G Finazzi; Christa Fonatsch; E Gluckman; Nicola Gökbuget; David Grimwade; Torsten Haferlach; M Hallek; Joerg Hasford; Dieter Hoelzer; P Ljungman; Dietger Niederwieser; Hubert Serve; B Simonsson; T J de Witte; Rüdiger Hehlmann
[Clinical research at the European LeukemiaNet].
Deutsche medizinische Wochenschrift (1946) 2006;131(43):2423-6.
2006: Christoph Walz; Claire Curtis; Susanne Schnittger; Beate Schultheis; Georgia Metzgeroth; Claudia Schoch; Eva Lengfelder; Philipp Erben; Martin C Müller; Torsten Haferlach; Andreas Hochhaus; Rüdiger Hehlmann; Nicholas C P Cross; Andreas Reiter
Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene.
Genes, chromosomes & cancer 2006;45(10):950-6.
2006: Florian Kuchenbauer; Susanne Schnittger; Thomas Look; G Gilliland; D Tenen; Torsten Haferlach; Wolfgang Hiddemann; Christian Buske; Claudia Schoch
Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO.
British journal of haematology 2006;134(6):616-9.
2006: Ulrike Bacher; Susanne Schnittger; Wolfgang Kern; Guido Trenn; Martin Weisser; Torsten Haferlach; Claudia Schoch
Acute myeloid leukemia (AML) with t(8;21)(q22;q22) relapsing as AML with t(3;21)(q26;q22).
Cancer genetics and cytogenetics 2006;168(2):172-4.
2006: Ulrike Bacher; Andreas Reiter; Torsten Haferlach; Lothar Mueller; Susanne Schnittger; Wolfgang Kern; Claudia Schoch
A combination of cytomorphology, cytogenetic analysis, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction for establishing clonality in cases of persisting hypereosinophilia.
Haematologica 2006;91(6):817-20.
2006: Thomas Büchner; Wolfgang E Berdel; Claudia Schoch; Torsten Haferlach; Hubert Serve; Joachim Kienast; Susanne Schnittger; Wolfgang Kern; Joëlle Tchinda; Albrecht Reichle; Eva Lengfelder; Peter Staib; Wolf-Dieter Ludwig; Carlo Aul; Hartmut Eimermacher; Leopold Balleisen; Maria Cristina Sauerland; Achim Heinecke; Bernhard Wörmann; Wolfgang Hiddemann
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(16):2480-9.
2006: Brunangelo Falini; Niccolò Bolli; Jing Shan; Maria Paola Martelli; Arcangelo Liso; Alessandra Pucciarini; Barbara Bigerna; Laura Pasqualucci; Roberta Mannucci; Roberto Rosati; Paolo Gorello; Daniela Diverio; Giovanni Roti; Enrico Tiacci; Giovanni Cazzaniga; Andrea Biondi; Suzanne Schnittger; Torsten Haferlach; Wolfgang Hiddemann; Massimo F Martelli; Wei Gu; Cristina Mecucci; Ildo Nicoletti
Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML.
Blood 2006;107(11):4514-23.
2006: Ulrike Bacher; Torsten Haferlach; Claudia Schoch; Wolfgang Kern; Susanne Schnittger
Implications of NRAS mutations in AML: a study of 2502 patients.
Blood 2006;107(10):3847-53.
2006: Susanne Schnittger; Tobias M Kohl; Nina Leopold; Claudia Schoch; H-Erich Wichmann; Wolfgang Kern; Peter Lohse; Wolfgang Hiddemann; Torsten Haferlach; Karsten Spiekermann
D324N single-nucleotide polymorphism in the FLT3 gene is associated with higher risk of myeloid leukemias.
Genes, chromosomes & cancer 2006;45(4):332-7.
2006: Susanne Schnittger; Tobias M Kohl; Torsten Haferlach; Wolfgang Kern; Wolfgang Hiddemann; Karsten Spiekermann; Claudia Schoch
KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival.
Blood 2006;107(5):1791-9.
2006: Ulrike Bacher; Wolfgang Kern; Claudia Schoch; Susanne Schnittger; Wolfgang Hiddemann; Torsten Haferlach
Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia.
Cancer 2006;106(4):839-47.
2006: Susanne Mueller; Stefan Holdenrieder; Petra Stieber; Torsten Haferlach; Andreas Schalhorn; Jan Braess; Dorothea Nagel; Dietrich Seidel
Early prediction of therapy response in patients with acute myeloid leukemia by nucleosomal DNA fragments.
BMC cancer 2006;6():143.
2006: Alexander Kohlmann; Wolfgang Kern; Wolfgang Hiddemann; Torsten Haferlach
Classification of AML by DNA-oligonucleotide microarrays.
Methods in molecular medicine 2006;125():213-40.
2005: Florian Kuchenbauer; Wolfgang Kern; Claudia Schoch; Alexander Kohlmann; Wolfgang Hiddemann; Torsten Haferlach; Susanne Schnittger
Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
Haematologica 2005;90(12):1617-25.
2005: Susanne Schnittger; Claudia Schoch; Wolfgang Kern; Cristina Mecucci; Claudia Tschulik; Massimo F Martelli; Torsten Haferlach; Wolfgang Hiddemann; Brunangelo Falini
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.
Blood 2005;106(12):3733-9.
2005: Ulrike Bacher; Wolfgang Kern; Susanne Schnittger; Wolfgang Hiddemann; Torsten Haferlach; Claudia Schoch
Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia.
Haematologica 2005;90(11):1502-10.
2005: Thomas Büchner; Wolfgang E Berdel; Bernhard Wörmann; Claudia Schoch; Torsten Haferlach; Susanne Schnittger; Wolfgang Kern; Carlo Aul; Eva Lengfelder; Andrea Schumacher; Albrecht Reichle; Peter Staib; Leopold Balleisen; Hartmut Eimermacher; Andreas Grüneisen; Herbert Rasche; Maria Cristina Sauerland; Achim Heinecke; Rolf M Mesters; Hubert Serve; Joachim Kienast; Wolfgang Hiddemann
Treatment of older patients with AML.
Critical reviews in oncology/hematology 2005;56(2):247-59.
2005: Torsten Haferlach; Wolfgang Kern; Susanne Schnittger; Claudia Schoch
Modern diagnostics in acute leukemias.
Critical reviews in oncology/hematology 2005;56(2):223-34.
2005: Wolfgang Kern; Claudia Schoch; Torsten Haferlach; Susanne Schnittger
Monitoring of minimal residual disease in acute myeloid leukemia.
Critical reviews in oncology/hematology 2005;56(2):283-309.
2005: Wolfgang Hiddemann; Karsten Spiekermann; Christian Buske; Michaela Feuring-Buske; Jan Braess; Torsten Haferlach; Claudia Schoch; Wolfgang Kern; Susanne Schnittger; Wolfgang E Berdel; Bernhard Wörmann; Achim Heinecke; Cristina Sauerland; Thomas Büchner
Towards a pathogenesis-oriented therapy of acute myeloid leukemia.
Critical reviews in oncology/hematology 2005;56(2):235-45.
2005: Ulrike Bacher; Wolfgang Kern; Susanne Schnittger; Wolfgang Hiddemann; Claudia Schoch; Torsten Haferlach
Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients.
Annals of hematology 2005;84(12):785-91.
2005: Torsten Haferlach; Alexander Kohlmann; Susanne Schnittger; Martin Dugas; Wolfgang Hiddemann; Wolfgang Kern; Claudia Schoch
Global approach to the diagnosis of leukemia using gene expression profiling.
Blood 2005;106(4):1189-98.
2005: Martin Weisser; Wolfgang Kern; S Rauhut; Claudia Schoch; Wolfgang Hiddemann; Torsten Haferlach; Susanne Schnittger
Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia.
Leukemia 2005;19(8):1416-23.
2005: Frank Dicker; Sonja Rauhut; Alexander Kohlmann; Wolfgang Kern; Claudia Schoch; Torsten Haferlach; Susanne Schnittger
Re: Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia.
Journal of the National Cancer Institute 2005;97(14):1092-3; author reply 1093-5.
2005: Ulrike Bacher; Torsten Haferlach; Claudia Schoch
Gain of 9p due to an unbalanced rearrangement der(9;18): a recurrent clonal abnormality in chronic myeloproliferative disorders.
Cancer genetics and cytogenetics 2005;160(2):179-83.
2005: Florian Kuchenbauer; Claudia Schoch; Wolfgang Kern; Wolfgang Hiddemann; Torsten Haferlach; Susanne Schnittger
Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia.
British journal of haematology 2005;130(2):196-202.
2005: Martin Weisser; Wolfgang Kern; Claudia Schoch; Wolfgang Hiddemann; Torsten Haferlach; Susanne Schnittger
Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy.
Haematologica 2005;90(7):881-9.
2005: Claudia Schoch; Alexander Kohlmann; Martin Dugas; Wolfgang Kern; Wolfgang Hiddemann; Susanne Schnittger; Torsten Haferlach
Genomic gains and losses influence expression levels of genes located within the affected regions: a study on acute myeloid leukemias with trisomy 8, 11, or 13, monosomy 7, or deletion 5q.
Leukemia 2005;19(7):1224-8.
2005: Claudia Schoch; Wolfgang Kern; Alexander Kohlmann; Wolfgang Hiddemann; Susanne Schnittger; Torsten Haferlach
Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile.
Genes, chromosomes & cancer 2005;43(3):227-38.
2005: Wolfgang Kern; Alexander Kohlmann; Susanne Schnittger; Claudia Schoch; Torsten Haferlach
Role of gene expression profiling for diagnosing acute leukemias.
Reviews in clinical and experimental hematology 2005;9(1):E1.
2005: Alexander Kohlmann; Claudia Schoch; Martin Dugas; Susanne Schnittger; Wolfgang Hiddemann; Wolfgang Kern; Torsten Haferlach
New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes.
Leukemia 2005;19(6):953-64.
2005: Torsten Haferlach; Alexander Kohlmann; Susanne Schnittger; Martin Dugas; Wolfgang Hiddemann; Wolfgang Kern; Claudia Schoch
AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypes.
Genes, chromosomes & cancer 2005;43(2):113-27.
2005: Gerhard Herzog; Juxian Lu-Hesselmann; Yvonne Zimmermann; Torsten Haferlach; Wolfgang Hiddemann; Martin Dreyling
Microsatellite instability and p53 mutations are characteristic of subgroups of acute myeloid leukemia but independent events.
Haematologica 2005;90(5):693-5.
2005: Ulrike Bacher; Susanne Schnittger; Wolfgang Kern; Wolfgang Hiddemann; Torsten Haferlach; Claudia Schoch
The incidence of submicroscopic deletions in reciprocal translocations is similar in acute myeloid leukemia, BCR-ABL positive acute lymphoblastic leukemia, and chronic myeloid leukemia.
Haematologica 2005;90(4):558-9.
2005: Ulrike Bacher; Torsten Haferlach; Wolfgang Kern; Wolfgang Hiddemann; Susanne Schnittger; Claudia Schoch
Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information.
Annals of hematology 2005;84(4):250-7.
2005: Wolfgang Kern; Torsten Haferlach; Susanne Schnittger; Claudia Schoch
Detection of t(14;18)(q32;q21) in B-cell chronic lymphocytic leukemia.
Archives of pathology & laboratory medicine 2005;129(3):410-1.
2005: Ulrike Bacher; Wolfgang Kern; Susanne Schnittger; Wolfgang Hiddemann; Claudia Schoch; Torsten Haferlach
Blast count and cytogenetics correlate and are useful parameters for the evaluation of different phases in chronic myeloid leukemia.
Leukemia & lymphoma 2005;46(3):357-66.
2005: Alexander Kohlmann; Claudia Schoch; Martin Dugas; Sonja Rauhut; Felix Weninger; Susanne Schnittger; Wolfgang Kern; Torsten Haferlach
Pattern robustness of diagnostic gene expression signatures in leukemia.
Genes, chromosomes & cancer 2005;42(3):299-307.
2005: Kai Neben; Susanne Schnittger; Benedikt Brors; Björn Tews; Felix Kokocinski; Torsten Haferlach; Jasmin Müller; Meinhard Hahn; Wolfgang Hiddemann; Roland Eils; Peter Lichter; Claudia Schoch
Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype.
Oncogene 2005;24(9):1580-8.
2005: W Kern; H Diem; Torsten Haferlach
[Immunophenotyping in modern leukemia diagnosis].
Deutsche medizinische Wochenschrift (1946) 2005;130(5):215-9.
2005: Ulrike Bacher; Torsten Haferlach; Wolfgang Hiddemann; Susanne Schnittger; Wolfgang Kern; Claudia Schoch
Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression.
Cancer genetics and cytogenetics 2005;157(1):53-61.
2005: Wolfgang Kern; Torsten Haferlach
[Quantification of minimal residual disease by multiparameter flow cytometry in acute myeloid leukemia. From diagnosis to prognosis].
Medizinische Klinik (Munich, Germany : 1983) 2005;100(1):54-9.
2005: Thomas Buechner; Wolfgang E Berdel; Claudia Schoch; Torsten Haferlach; Hubert Serve; Susanne Schnittger; Wolfgang Kern; Joëlle Tchinda; Albrecht Reichle; Peter Staib; Wolf-Dieter Ludwig; Carlo Aul; Maria Cristina Sauerland; Achim Heinecke; Bernhard Woermann; Wolfgang Hiddemann
Treatment of AML in biological subgroups.
Hematology (Amsterdam, Netherlands) 2005;10 Suppl 1():281-85.
2004: Georg Lenz; Martin Dreyling; Eva Schiegnitz; Torsten Haferlach; Joerg Hasford; Michael Unterhalt; Wolfgang Hiddemann
Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(24):4926-33.
2004: Wolfgang Kern; Daniela Voskova; Claudia Schoch; Wolfgang Hiddemann; Susanne Schnittger; Torsten Haferlach
Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia.
Blood 2004;104(10):3078-85.
2004: Mirjam Klaus; Torsten Haferlach; Susanne Schnittger; Wolfgang Kern; Wolfgang Hiddemann; Claudia Schoch
Cytogenetic profile in de novo acute myeloid leukemia with FAB subtypes M0, M1, and M2: a study based on 652 cases analyzed with morphology, cytogenetics, and fluorescence in situ hybridization.
Cancer genetics and cytogenetics 2004;155(1):47-56.
2004: Daniela Voskova; Claudia Schoch; Susanne Schnittger; Wolfgang Hiddemann; Torsten Haferlach; Wolfgang Kern
Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings.
Cytometry. Part B, Clinical cytometry 2004;62(1):25-38.
2004: Claudia Schoch; Wolfgang Kern; Susanne Schnittger; Thomas Büchner; Wolfgang Hiddemann; Torsten Haferlach
The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups.
Haematologica 2004;89(9):1082-90.
2004: Ulrich Jehn; Reiner Bartl; H Dietzfelbinger; Torsten Haferlach; Volker Heinemann
An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine.
Leukemia 2004;18(9):1476-81.
2004: Torsten Haferlach
[Molecular classification in leukemias using gene expression profiling].
Medizinische Klinik (Munich, Germany : 1983) 2004;99(8):464-6.
2004: Wolfgang Kern; Torsten Haferlach; Susanne Schnittger; Wolfgang Hiddemann; Claudia Schoch
Prognosis in therapy-related acute myeloid leukemia and impact of karyotype.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(12):2510-1.
2004: Ulrike Bacher; Wolfgang Kern; Claudia Schoch; Wolfgang Hiddemann; Torsten Haferlach
Discrimination of chronic lymphocytic leukemia (CLL) and CLL/PL by cytomorphology can clearly be correlated to specific genetic markers as investigated by interphase fluorescence in situ hybridization (FISH).
Annals of hematology 2004;83(6):349-55.
2004: J Christodoulou; Claudia Schoch; Susanne Schnittger; Torsten Haferlach
Myelodysplastic syndrome (RARS) with +i(12p) abnormality in a patient 10 months after diagnosis and successful treatment of a mediastinal germ cell tumor (MGCT).
Annals of hematology 2004;83(6):386-9.
2004: Wolfgang Kern; Daniela Voskova; Claudia Schoch; Susanne Schnittger; Wolfgang Hiddemann; Torsten Haferlach
Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia.
Haematologica 2004;89(5):528-40.
2004: David Grimwade; Torsten Haferlach
Gene-expression profiling in acute myeloid leukemia.
The New England journal of medicine 2004;350(16):1676-8.
2004: Torsten Haferlach; Wolfgang Kern; Claudia Schoch; Susanne Schnittger; Maria Cristina Sauerland; Achim Heinecke; Thomas Büchner; Wolfgang Hiddemann
A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group.
Haematologica 2004;89(4):408-18.
2004: Axel Glasmacher; Hartmut Goldschmidt; Jörg Mezger; Torsten Haferlach; Ingo G H Schmidt-Wolf; Frank Gieseler
Oral idarubicin, dexamethasone and vincristine in the treatment of multiple myeloma: final analysis of a phase II trial.
Haematologica 2004;89(3):371-3.
2004: Ingo Tamm; Stephan Richter; Frank Scholz; Karin Schmelz; Doreen Oltersdorf; Leonid Karawajew; Claudia Schoch; Torsten Haferlach; Wolf-Dieter Ludwig; Christian Wuchter
XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis.
The hematology journal : the official journal of the European Haematology Association / EHA 2004;5(6):489-95.
2004: Wolfgang Kern; Daniela Voskova; Susanne Schnittger; Claudia Schoch; Wolfgang Hiddemann; Torsten Haferlach
Four-fold staining including CD45 gating improves the sensitivity of multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia.
The hematology journal : the official journal of the European Haematology Association / EHA 2004;5(5):410-8.
2004: Wolfgang Kern; Alexander Kohlmann; Susanne Schnittger; Wolfgang Hiddemann; Claudia Schoch; Torsten Haferlach
Gene expression profiling as a diagnostic tool in acute myeloid leukemia.
American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 2004;4(4):225-37.
2004: Susanne Schnittger; Claudia Schoch; Wolfgang Kern; Wolfgang Hiddemann; Torsten Haferlach
FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia.
Acta haematologica 2004;112(1-2):68-78.
2004: Thomas Büchner; Wolfgang Hiddemann; Wolfgang E Berdel; Bernhard Wörmann; Claudia Schoch; Christa Fonatsch; Helmut Löffler; Torsten Haferlach; Wolf-Dieter Ludwig; Georg Maschmeyer; Peter Staib; Leopold Balleisen; Andreas Grüneisen; Carlo Aul; Eva Lengfelder; Rüdiger Hehlmann; Wolfgang Kern; Hubert Serve; Rolf M Mesters; Hartmut Eimermacher; Norbert Frickhofen; Joachim Kienast; A Giagounidis; Maria Cristina Sauerland; Achim Heinecke
Subgroup specific therapy effects in AML: AMLCG data.
Annals of hematology 2004;83 Suppl 1():S100-1.
2004: Torsten Haferlach; Wolfgang Kern; Susanne Schnittger; Claudia Schoch
Modern diagnostics in chronic myeloproliferative diseases (CMPDs).
Annals of hematology 2004;83 Suppl 1():S59-61.
2004: W Kern; Torsten Haferlach; Claudia Schoch; Maria Cristina Sauerland; Achim Heinecke; Bernhard Wörmann; Wolfgang E Berdel; Thomas Büchner; Wolfgang Hiddemann
Risk-adapted therapy of AML: the AMLCG experience.
Annals of hematology 2004;83 Suppl 1():S49-51.
2004: Alexander Kohlmann; Claudia Schoch; Susanne Schnittger; Martin Dugas; Wolfgang Hiddemann; Wolfgang Kern; Torsten Haferlach
Pediatric acute lymphoblastic leukemia (ALL) gene expression signatures classify an independent cohort of adult ALL patients.
Leukemia 2004;18(1):63-71.
2004: Claudia Schoch; Wolfgang Kern; Susanne Schnittger; Wolfgang Hiddemann; Torsten Haferlach
Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML.
Leukemia 2004;18(1):120-5.
2003: Thomas Büchner; Wolfgang Hiddemann; Wolfgang E Berdel; Bernhard Wörmann; Claudia Schoch; Christa Fonatsch; Helmut Löffler; Torsten Haferlach; Wolf-Dieter Ludwig; Georg Maschmeyer; Peter Staib; Carlo Aul; Andreas Gruneisen; Eva Lengfelder; Norbert Frickhofen; Wolfgang Kern; Hubert Serve; Rolf M Mesters; Maria Cristina Sauerland; Achim Heinecke
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(24):4496-504.
2003: Georg Lenz; Alexander Golf; Thomas Rüdiger; Wolfgang Hiddemann; Torsten Haferlach
Epstein-Barr virus-associated B-cell non-Hodgkin lymphoma following treatment of hairy cell leukemia with cladribine.
Blood 2003;102(9):3457-8.
2003: Susanne Schnittger; Martin Weisser; Claudia Schoch; Wolfgang Hiddemann; Torsten Haferlach; Wolfgang Kern
New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts.
Blood 2003;102(8):2746-55.
2003: Torsten Haferlach; Alexander Kohlmann; Wolfgang Kern; Wolfgang Hiddemann; Susanne Schnittger; Claudia Schoch
Gene expression profiling as a tool for the diagnosis of acute leukemias.
Seminars in hematology 2003;40(4):281-95.
2003: Claudia Schoch; Susanne Schnittger; Mirjam Klaus; Wolfgang Kern; Wolfgang Hiddemann; Torsten Haferlach
AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases.
Blood 2003;102(7):2395-402.
2003: Katharina Tschoep; Alexander Kohlmann; Marcus Schlemmer; Torsten Haferlach; Rolf Issels
[Gene expression analysis using DNA microarrays in soft tissue and bone tumors].
Deutsche medizinische Wochenschrift (1946) 2003;128(39):2030-6.
2003: Wolfgang Kern; Alexander Kohlmann; Christian Wuchter; Susanne Schnittger; Claudia Schoch; Susanne Mergenthaler; Richard Ratei; Wolf-Dieter Ludwig; Wolfgang Hiddemann; Torsten Haferlach
Correlation of protein expression and gene expression in acute leukemia.
Cytometry. Part B, Clinical cytometry 2003;55(1):29-36.
2003: Michael Fiegl; Christina Rieger; Jan Braess; Torsten Haferlach; Susanne Schnittger; Claudia Schoch; Wolfgang Hiddemann; Helmut Ostermann
Isolated epidural chloroma with translocation t(15; 17) successfully treated with chemotherapy and all-trans-retinoic acid.
British journal of haematology 2003;122(4):688-9.
2003: Alexander Kohlmann; Claudia Schoch; Susanne Schnittger; Martin Dugas; Wolfgang Hiddemann; Wolfgang Kern; Torsten Haferlach
Molecular characterization of acute leukemias by use of microarray technology.
Genes, chromosomes & cancer 2003;37(4):396-405.
2003: Janki Rangatia; Rajani K Vangala; Sheo M Singh; Abdul A Peer Zada; Annika Elsässer; Alexander Kohlmann; Torsten Haferlach; Daniel G Tenen; Wolfgang Hiddemann; Gerhard Behre
Elevated c-Jun expression in acute myeloid leukemias inhibits C/EBPalpha DNA binding via leucine zipper domain interaction.
Oncogene 2003;22(30):4760-4.
2003: Mirjam Klaus; Susanne Schnittger; Torsten Haferlach; Martin Dreyling; Wolfgang Hiddemann; Claudia Schoch
Cytogenetics, fluorescence in situ hybridization, and reverse transcriptase polymerase chain reaction are necessary to clarify the various mechanisms leading to an MLL-AF10 fusion in acute myelocytic leukemia with 10;11 rearrangement.
Cancer genetics and cytogenetics 2003;144(1):36-43.
2003: Wolfgang Kern; Susanne Danhauser-Riedl; Richard Ratei; Susanne Schnittger; Claudia Schoch; Hans-Jochem Kolb; Wolf-Dieter Ludwig; Wolfgang Hiddemann; Torsten Haferlach
Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow.
Haematologica 2003;88(6):646-53.
2003: Abdul Ali Peer Zada; Sheo M Singh; Venkateshwar A Reddy; Annika Elsässer; Alexander Meisel; Torsten Haferlach; Daniel G Tenen; Wolfgang Hiddemann; Gerhard Behre
Downregulation of c-Jun expression and cell cycle regulatory molecules in acute myeloid leukemia cells upon CD44 ligation.
Oncogene 2003;22(15):2296-308.
2003: Mathias Gehrmann; Helga Schmetzer; Günther Eissner; Torsten Haferlach; Wolfgang Hiddemann; Gabriele Multhoff
Membrane-bound heat shock protein 70 (Hsp70) in acute myeloid leukemia: a tumor specific recognition structure for the cytolytic activity of autologous NK cells.
Haematologica 2003;88(4):474-6.
2003: Claudia Schoch; Susanne Schnittger; Wolfgang Kern; Martin Dugas; Wolfgang Hiddemann; Torsten Haferlach
Acute myeloid leukemia with recurring chromosome abnormalities as defined by the WHO-classification: incidence of subgroups, additional genetic abnormalities, FAB subtypes and age distribution in an unselected series of 1,897 patients with acute myeloid leukemia.
Haematologica 2003;88(3):351-2.
2003: Torsten Haferlach; Claudia Schoch; Helmut Löffler; Winfried Gassmann; Wolfgang Kern; Susanne Schnittger; Christa Fonatsch; Wolf-Dieter Ludwig; Christian Wuchter; Brigitte Schlegelberger; Peter Staib; Albrecht Reichle; Uschi Kubica; Hartmut Eimermacher; Leopold Balleisen; Andreas Grüneisen; Detlef Haase; Carlo Aul; Jochen Karow; Eva Lengfelder; Bernhard Wörmann; Achim Heinecke; Maria Cristina Sauerland; Thomas Büchner; Wolfgang Hiddemann
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(2):256-65.
2003: Wolfgang Kern; Torsten Haferlach; Claudia Schoch; Helmut Loffler; Winfried Gassmann; Achim Heinecke; Maria Cristina Sauerland; Wolfgang E Berdel; Thomas Buchner; Wolfgang Hiddemann
Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.
Blood 2003;101(1):64-70.
2002: Karsten Spiekermann; Ksenia Bagrintseva; Claudia Schoch; Torsten Haferlach; Wolfgang Hiddemann; Susanne Schnittger
A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia.
Blood 2002;100(9):3423-5.
2002: Alexander Kohlmann; Claudia Schoch; Susanne Schnittger; W Kern; Torsten Haferlach
[Diagnosis of leukemia using microarray technology].
Deutsche medizinische Wochenschrift (1946) 2002;127(42):2216-22.
2002: Torsten Haferlach; Claudia Schoch
[Modern techniques in leukemia diagnosis].
Der Internist 2002;43(10):1190, 1193-6, 1199-202.
2002: Wolfgang Kern; Torsten Haferlach; Susanne Schnittger; W D Ludwig; Wolfgang Hiddemann; Claudia Schoch
Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy.
Leukemia 2002;16(10):2084-91.
2002: Claudia Schoch; Torsten Haferlach; Sabina Bursch; Daniela Gerstner; Susanne Schnittger; Martin Dugas; Wolfgang Kern; Helmut Löffler; Wolfgang Hiddemann
Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH.
Genes, chromosomes & cancer 2002;35(1):20-9.
2002: Raymund Buhmann; Christian Kurzeder; Jutta Rehklau; Doreen Westhaus; Sabina Bursch; Wolfgang Hiddemann; Torsten Haferlach; Michael Hallek; Claudia Schoch
CD40L stimulation enhances the ability of conventional metaphase cytogenetics to detect chromosome aberrations in B-cell chronic lymphocytic leukaemia cells.
British journal of haematology 2002;118(4):968-75.
2002: Claudia Schoch; Torsten Haferlach
Cytogenetics in acute myeloid leukemia.
Current oncology reports 2002;4(5):390-7.
2002: Torsten Haferlach; Claudia Schoch; Susanne Schnittger; Wolfgang Kern; Helmut Löffler; Wolfgang Hiddemann
Distinct genetic patterns can be identified in acute monoblastic and acute monocytic leukaemia (FAB AML M5a and M5b): a study of 124 patients.
British journal of haematology 2002;118(2):426-31.
2002: Claudia Schoch; Alexander Kohlmann; Susanne Schnittger; Benedikt Brors; Martin Dugas; Susanne Mergenthaler; Wolfgang Kern; Wolfgang Hiddemann; Roland Eils; Torsten Haferlach
Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(15):10008-13.
2002: Susanne Schnittger; Claudia Schoch; Martin Dugas; Wolfgang Kern; Peter Staib; Christian Wuchter; Helmut Löffler; Cristina Sauerland; Hubert Serve; Thomas Büchner; Torsten Haferlach; Wolfgang Hiddemann
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.
Blood 2002;100(1):59-66.
2002: Helmut R Salih; Gary C Starling; Stephan F Brandl; Renate Pelka-Fleischer; Torsten Haferlach; Wolfgang Hiddemann; Peter Kiener; Volkmar Nuessler
Differentiation of promyelocytic leukaemia: alterations in Fas (CD95/Apo-1) and Fas ligand (CD178) expression.
British journal of haematology 2002;117(1):76-85.
2002: Thomas Büchner; Wolfgang Hiddemann; Wolfgang E Berdel; Bernhard Wörmann; Claudia Schoch; Helmut Löffler; Torsten Haferlach; Andrea Schumacher; Peter Staib; Leopold Balleisen; Andreas Grüneisen; Herbert Rasche; Carlo Aul; Axel Heyll; Eva Lengfelder; Wolf-Dieter Ludwig; Georg Maschmeyer; Hartmut Eimermacher; Jochen Karow; Norbert Frickhofen; Wolf-Dietrich Hirschmann; Maria Cristina Sauerland
Acute myeloid leukemia: treatment over 60.
Reviews in clinical and experimental hematology 2002;6(1):46-59; discussion 86-7.
2002: Torsten Haferlach; Claudia Schoch
[WHO classification of acute myeloid leukaemia (AML) and the myelodysplastic syndrome (MDS)].
Deutsche medizinische Wochenschrift (1946) 2002;127(9):447-50.
2002: Martin Dugas; Claudia Schoch; Susanne Schnittger; Alexander Kohlmann; Wolfgang Kern; Torsten Haferlach; Karl Uberla
Impact of integrating clinical and genetic information.
In silico biology 2002;2(3):383-91.
2002: Claudia Schoch; Susanne Schnittger; Wolfgang Kern; Eva Lengfelder; Helmut Löffler; Wolfgang Hiddemann; Torsten Haferlach
Rapid diagnostic approach to PML-RARalpha-positive acute promyelocytic leukemia.
The hematology journal : the official journal of the European Haematology Association / EHA 2002;3(5):259-63.
2002: Claudia Schoch; Susanne Schnittger; Sabina Bursch; D Gerstner; A Hochhaus; U Berger; R Hehlmann; Wolfgang Hiddemann; Torsten Haferlach
Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases.
Leukemia 2002;16(1):53-9.
2001: Robert Schoch; J Pitako; P Schafhausen; Stefan Jenisch; Torsten Haferlach; Michael Kneba; Meinolf Suttorp
Semiquantitative reverse transcription polymerase chain reaction analysis for detection of bcr/abl rearrangement using RNA extracts from bone marrow aspirates compared with glass slide smears after 0, 2 and 4 d of storage.
British journal of haematology 2001;115(3):583-7.
2001: Thomas Büchner; Wolfgang Hiddemann; Wolfgang E Berdel; Bernhard Wörmann; Helmut Löffler; Claudia Schoch; Torsten Haferlach; Wolf-Dieter Ludwig; Georg Maschmeyer; Peter Staib; R Andreesen; Leopold Balleisen; Detlef Haase; Hartmut Eimermacher; Carlo Aul; Herbert Rasche; J Uhlig; Andreas Grüneisen; H E Reis; J Hartlapp; Wolf-Dietrich Hirschmann; H J Weh; H J Pielken; Winfried Gassmann; Maria Cristina Sauerland; Achim Heinecke
Remission induction therapy: the more intensive the better?
Cancer chemotherapy and pharmacology 2001;48 Suppl 1():S41-4.
2001: Jan Braess; G Jahns-Streubel; Claudia Schoch; Detlef Haase; Torsten Haferlach; Michael Fiegl; S Voss; Wolfgang Kern; Eberhard Schleyer; Wolfgang Hiddemann
Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia.
British journal of haematology 2001;113(4):975-82.
2001: Claudia Schoch; Sabina Bursch; Wolfgang Kern; Susanne Schnittger; Wolfgang Hiddemann; Torsten Haferlach
Gain of an isochromosome 5p: a new recurrent chromosome abnormality in acute monoblastic leukemia.
Cancer genetics and cytogenetics 2001;127(1):85-8.
2001: Christian Wuchter; Richard Ratei; G Spahn; Claudia Schoch; Jochen Harbott; Susanne Schnittger; Torsten Haferlach; U Creutzig; C Sperling; Leonid Karawajew; Wolf-Dieter Ludwig
Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping.
Haematologica 2001;86(2):154-61.
2001: Claudia Schoch; Torsten Haferlach; Detlef Haase; Christa Fonatsch; Helmut Löffler; Brigitte Schlegelberger; Peter Staib; Maria Cristina Sauerland; Achim Heinecke; Thomas Büchner; Wolfgang Hiddemann
Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients.
British journal of haematology 2001;112(1):118-26.
2001: Torsten Haferlach
Quantitative reverse transcriptase-polymerase chain reaction in AML with t(8;21)(q22;q22).
Leukemia research 2001;25(1):55-56.
2000: Thomas Büchner; Wolfgang Hiddemann; Bernhard Wörmann; Helmut Löffler; Wolf-Dieter Ludwig; Claudia Schoch; Torsten Haferlach; Georg Maschmeyer; Peter Staib; Carlo Aul; G A Heyll; Andreas Grüneisen; Herbert Rasche; J H Eimermacher; Leopold Balleisen; H J Pielken; H E Reis; Frank Griesinger; Albrecht Reichle; Maria Cristina Sauerland; Achim Heinecke
Acute myeloid leukemia in adults: is postconsolidation maintenance therapy necessary?
International journal of hematology 2000;72(3):285-9.
2000: Eva Lengfelder; Anja Reichert; Claudia Schoch; Detlef Haase; Torsten Haferlach; Helmut Löffler; Peter Staib; Axel Heyll; Wolfgang Seifarth; Susanne Saussele; Christa Fonatsch; Winfried Gassmann; Wolf-Dieter Ludwig; Andreas Hochhaus; D Beelen; Carlo Aul; Maria Cristina Sauerland; Achim Heinecke; Rüdiger Hehlmann; Bernhard Wörmann; Wolfgang Hiddemann; Thomas Büchner
Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group.
Leukemia 2000;14(8):1362-70.
2000: Jan Braess; S Voss; G Jahns-Streubel; Claudia Schoch; Torsten Haferlach; Wolfgang Kern; S Keye; Eberhard Schleyer; Wolfgang Hiddemann
The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with a high proliferative activity.
British journal of haematology 2000;110(1):170-9.
2000: Christian Wuchter; Jochen Harbott; Claudia Schoch; Susanne Schnittger; Arndt Borkhardt; Leonid Karawajew; Richard Ratei; Velia Ruppert; Torsten Haferlach; U Creutzig; Bernd Dörken; Wolf-Dieter Ludwig
Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1.
Leukemia 2000;14(7):1232-8.
2000: Christian Wuchter; K Leonid; Velia Ruppert; Martin Schrappe; Thomas Büchner; Claudia Schoch; Torsten Haferlach; Jochen Harbott; Richard Ratei; Bernd Dörken; Wolf-Dieter Ludwig
Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.
Haematologica 2000;85(7):711-21.
2000: Susanne Schnittger; U Kinkelin; Claudia Schoch; Achim Heinecke; Detlef Haase; Torsten Haferlach; Thomas Büchner; Bernhard Wörmann; Wolfgang Hiddemann; Frank Griesinger
Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML.
Leukemia 2000;14(5):796-804.
1999: Christian Wuchter; Leonid Karawajew; Velia Ruppert; Thomas Büchner; Claudia Schoch; Torsten Haferlach; Richard Ratei; Bernd Dörken; Wolf-Dieter Ludwig
Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics.
Leukemia 1999;13(12):1943-53.
1999: Thomas Büchner; Wolfgang Hiddemann; Bernhard Wörmann; Helmut Löffler; Winfried Gassmann; Torsten Haferlach; Christa Fonatsch; Detlef Haase; Claudia Schoch; Dieter K Hossfeld; Eva Lengfelder; Carlo Aul; Axel Heyll; Georg Maschmeyer; Wolf-Dieter Ludwig; Maria Cristina Sauerland; Achim Heinecke
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
Blood 1999;93(12):4116-24.
1999: B Gahn; B Wendenburg; C Troff; J Neef; D Grove; Torsten Haferlach; Wolfgang Hiddemann; Bernhard Wörmann
Analysis of progenitor cell involvement in B-CLL by simultaneous immunophenotypic and genotypic analysis at the single cell level.
British journal of haematology 1999;105(4):955-9.
1998: Torsten Haferlach; Helmut Löffler; C Nickenig; L Ramm-Petersen; M Meeder; R Schoch; Brigitte Schlegelberger; Susanne Schnittger; Claudia Schoch; Wolfgang Hiddemann
Cell lineage specific involvement in acute promyelocytic leukaemia (APL) using a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques for the detection of the translocation t(15;17)(q22;q12).
British journal of haematology 1998;103(1):93-9.
1997: Axel Glasmacher; Torsten Haferlach; Marcus Gorschlüter; Jörg Mezger; C Maintz; M R Clemens; Y Ko; Corinna Hahn; R Ubelacker; Rolf Kleinschmidt; Frank Gieseler
Oral idarubicin, dexamethasone and vincristine (VID) in the treatment of multiple myeloma.
Leukemia 1997;11 Suppl 5():S22-6.
1997: Torsten Haferlach; Helmut Löffler
Prognostic factors in multiple myeloma: practicability for clinical practice and future perspectives.
Leukemia 1997;11 Suppl 5():S5-9.
1997: Claudia Schoch; Detlef Haase; Christa Fonatsch; Torsten Haferlach; Helmut Löffler; Brigitte Schlegelberger; Dieter K Hossfeld; R Becher; Maria Cristina Sauerland; Achim Heinecke; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
The significance of trisomy 8 in de novo acute myeloid leukaemia: the accompanying chromosome aberrations determine the prognosis. German AML Cooperative Study Group.
British journal of haematology 1997;99(3):605-11.
1997: Torsten Haferlach; M Winkemann; L Ramm-Petersen; M Meeder; R Schoch; K Weber-Matthiesen; Brigitte Schlegelberger; Claudia Schoch; Wolf-Dieter Ludwig; Wolfgang Hiddemann; Helmut Löffler
New insights into the biology of Philadelphia-chromosome-positive acute lymphoblastic leukaemia using a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques at the single cell level.
British journal of haematology 1997;99(2):452-9.
1997: Torsten Haferlach; Wolfgang Hiddemann
[Liver involvement in hematologic diseases].
Der Internist 1997;38(10):977-83.
1997: Winfried Gassmann; Helmut Löffler; Eckhard Thiel; Wolf-Dieter Ludwig; Stefan Schwartz; Torsten Haferlach; J Maurer; Harald Rieder; Christa Fonatsch; Nicola Gökbuget; Dieter Hoelzer
Morphological and cytochemical findings in 150 cases of T-lineage acute lymphoblastic leukaemia in adults. German Multicentre ALL Study Group (GMALL).
British journal of haematology 1997;97(2):372-82.
1997: Torsten Haferlach; M Winkemann; C Nickenig; M Meeder; L Ramm-Petersen; R Schoch; M Nickelsen; K Weber-Matthiesen; Brigitte Schlegelberger; Claudia Schoch; Winfried Gassmann; H Loffler
Which compartments are involved in Philadelphia-chromosome positive chronic myeloid leukaemia? An answer at the single cell level by combining May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques.
British journal of haematology 1997;97(1):99-106.
1996: Torsten Haferlach; J M Bennett; Helmut Löffler; Winfried Gassmann; J W Andersen; NUKHET TUZUNER; P A Casslleth; Christa Fonatsch; Claudia Schoch; Brigitte Schlegelberger; R Becher; Eckhard Thiel; Wolf-Dieter Ludwig; Maria Cristina Sauerland; Achim Heinecke; Thomas Büchner
Acute myeloid leukemia with translocation (8;21). Cytomorphology, dysplasia and prognostic factors in 41 cases. AML Cooperative Group and ECOG.
Leukemia & lymphoma 1996;23(3-4):227-34.
1996: Claudia Schoch; Detlef Haase; Torsten Haferlach; Mathias Freund; H Link; Eva Lengfelder; Helmut Löffler; Thomas Büchner; Christa Fonatsch
Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report on 50 patients.
British journal of haematology 1996;94(3):493-500.
1996: Claudia Schoch; Detlef Haase; Torsten Haferlach; H Gudat; Thomas Büchner; Mathias Freund; H Link; Eva Lengfelder; Hannes Wandt; Maria Cristina Sauerland; Helmut Löffler; Christa Fonatsch
Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor.
Leukemia 1996;10(8):1288-95.
1996: Torsten Haferlach
More individual markers are necessary for patients with acute myeloid leukemia (AML). Does cytomorphology or cytogenetics define the biological entity?
Leukemia 1996;10 Suppl 3():S5-S9.
1996: Torsten Haferlach; M Winkemann; Helmut Löffler; R Schoch; Winfried Gassmann; Christa Fonatsch; Claudia Schoch; M Poetsch; K Weber-Matthiesen; Brigitte Schlegelberger
The abnormal eosinophils are part of the leukemic cell population in acute myelomonocytic leukemia with abnormal eosinophils (AML M4Eo) and carry the pericentric inversion 16: a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridization.
Blood 1996;87(6):2459-63.
1996: Y Zhang; M Poetsch; K Weber-Matthiesen; K Rohde; M Winkemann; Torsten Haferlach; Winfried Gassmann; Wolf-Dieter Ludwig; Werner Grote; Helmut Löffler; Brigitte Schlegelberger
Secondary acute leukaemias with 11q23 rearrangement: clinical, cytogenetic, FISH and FICTION studies.
British journal of haematology 1996;92(3):673-80.
1996: M G Wichmann; Torsten Haferlach; M Suttorp; Y Zhang; Juergen Neppert
Can blood group O red cells of donor origin acquire weak group A reactivity through serum A transferase of the recipient after bone marrow transplantation?
Infusionstherapie und Transfusionsmedizin 1996;23(1):29-31.
1996: Brigitte Schlegelberger; T Zwingers; K Hohenadel; D Henne-Bruns; Norbert Schmitz; Torsten Haferlach; C Tirier; H Bartels; Ruth Sonnen; Rolf Kuse
Significance of cytogenetic findings for the clinical outcome in patients with T-cell lymphoma of angioimmunoblastic lymphadenopathy type.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(2):593-9.
1996: R Schoch; Stefan Jenisch; Torsten Haferlach; Wolfgang Müller-Ruchholtz; Winfried Gassmann; Helmut Löffler
Glass slide smears are a suitable source for RT-PCR-based analysis of chromosomal aberrations in leukaemias.
British journal of haematology 1996;92(1):140-2.
1996: Axel Hauschild; Torsten Haferlach; Helmut Löffler; Enno Christophers
Multiple myeloma first presenting as cutaneous plasmacytoma.
Journal of the American Academy of Dermatology 1996;34(1):146-8.
1995: Peter Dreger; M Klöss; B Petersen; Torsten Haferlach; Helmut Löffler; Markus Loeffler; Norbert Schmitz
Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts.
Blood 1995;86(10):3970-8.
1995: Norbert Schmitz; Peter Dreger; M Suttorp; E B Rohwedder; Torsten Haferlach; Helmut Löffler; A Hunter; N H Russell
Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor)
Blood 1995;85(6):1666-72.
1995: Helmut Löffler; Winfried Gassmann; Torsten Haferlach
AML M1 and M2 with eosinophilia and AML M4Eo: diagnostic and clinical aspects.
Leukemia & lymphoma 1995;18 Suppl 1():61-3.
1994: Peter Dreger; Torsten Haferlach; V Eckstein; S Jacobs; M Suttorp; Helmut Löffler; Wolfgang Müller-Ruchholtz; Norbert Schmitz
G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft.
British journal of haematology 1994;87(3):609-13.
1994: M G Wichmann; Torsten Haferlach; M Suttorp; Y Zhang; Juergen Neppert
Can blood group O red cells of donor origin acquire weak group A reactivity through serum A transferase of the recipient after bone marrow transplantation?
Beiträge zur Infusionstherapie und Transfusionsmedizin = Contributions to infusion therapy and transfusion medicine 1994;32():146-8.
1993: Peter Dreger; P Marquardt; Torsten Haferlach; S Jacobs; T Mülverstedt; V Eckstein; M Suttorp; Helmut Löffler; Wolfgang Müller-Ruchholtz; Norbert Schmitz
Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product.
British journal of cancer 1993;68(5):950-7.
1993: Torsten Haferlach; Helmut Löffler; Bertram Glaß; Winfried Gassmann
Repeated complete remission in a patient with acute promyelocytic leukemia after treatment with 13-cis-retinoic acid first and with all-trans-retinoic acid in relapse.
The Clinical investigator 1993;71(10):774-9.
1993: Norbert Schmitz; Bertram Glaß; Peter Dreger; Torsten Haferlach; H A Horst; J Ollech-Chwoyka; M Suttorp; Winfried Gassmann; H Löffler
High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease.
Annals of hematology 1993;66(5):251-6.
1993: Torsten Haferlach; Winfried Gassmann; Helmut Löffler; C Jürgensen; J Noak; Wolf-Dieter Ludwig; Eckhard Thiel; Detlef Haase; Christa Fonatsch; R Becher
Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo. The AML Cooperative Group.
Annals of hematology 1993;66(4):165-70.
1993: Peter Dreger; M Suttorp; Torsten Haferlach; H Löffler; Norbert Schmitz; W Schroyens
Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation.
Blood 1993;81(5):1404-7.
1991: Norbert Schmitz; E Prange; Torsten Haferlach; H Griesser; Ruth Sonnen; Brigitte Schlegelberger; S Claus; Helmut Löffler
High-dose chemotherapy and autologous bone marrow transplantation in relapsing angioimmunoblastic lymphadenopathy with dysproteinemia (AILD).
Bone marrow transplantation 1991;8(6):503-6.
1991: P von Wussow; Hans Pralle; H K Hochkeppel; D Jakschies; S Sonnen; H Schmidt; D Müller-Rosenau; M Franke; Torsten Haferlach; T Zwingers
Effective natural interferon-alpha therapy in recombinant interferon-alpha-resistant patients with hairy cell leukemia.
Blood 1991;78(1):38-43.
1986: Helmut Löffler; W Gassmann; Torsten Haferlach; Hans Pralle
[A comparison of staging classifications of plasmacytoma].
Onkologie 1986;9(4):196, 199-201.
1985: W Gassmann; Hans Pralle; Torsten Haferlach; S Pandurevic; M Graubner; Norbert Schmitz; Helmut Löffler
Staging systems for multiple myeloma: a comparison.
British journal of haematology 1985;59(4):703-11.